Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOM: mFOLFOX6 + Bevacizumab vs Cetuximab in Colorectal Liver Metastasis
NCT01836653Phase 2Completed
- Sponsor
- EPS Corporation
- Start
- May 2013
- Primary completion
- Mar 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, KL-140 in colorectal cancer (CRC), sponsored by EPS Corporation. Started May 2013; status: completed.
02
Drugs
bevacizumabKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01836653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01836653.